Table 3 Final adjusted logistic regression model
b | OR | CI 95% | p value | ||
|---|---|---|---|---|---|
Present vs. Absent | |||||
Age, years | 0.028 | 1.03 | 1.02 | 1.04 | < 0.001 |
Duration of DM, years | 0.067 | 1.07 | 1.05 | 1.09 | < 0.001 |
HbA1c (%) | 0.216 | 1.24 | 1.17 | 1.32 | < 0.001 |
Serum uric acid, mg/dL | 0.196 | 1.22 | 1.13 | 1.31 | < 0.001 |
Use of an angiotensin-converting enzyme (ACE) inhibitor, yes | 0.563 | 1.78 | 1.26 | 2.43 | < 0.001 |
Macrovascular disease, yes | 0.813 | 2.26 | 1.08 | 4.71 | 0.03 |
Arterial hypertension, yes | 0.521 | 1.68 | 1.13 | 2.5 | 0.01 |
VTDR vs. Non-VTDR | |||||
Duration of DM, years | 0.075 | 1.08 | 1.06 | 1.1 | < 0.001 |
HbA1c % | 0.105 | 1.11 | 1.02 | 1.21 | 0.014 |
Serum uric acid, mg/dL | 0.219 | 1.25 | 1.13 | 1.37 | < 0.001 |
Use of an angiotensin-converting enzyme (ACE) inhibitor yes | 0.774 | 2.17 | 1.51 | 3.11 | < 0.001 |
LDL cholesterol, mg/dL | −0.01 | 0.99 | 0.99 | 1 | 0.019 |
Chronic kidney disease, yes | 0.925 | 2.52 | 1.69 | 3.77 | < 0.001 |